Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07197827) titled 'A Study of YL242 in Subjects With Advanced Solid Tumors' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Condition:
Advanced Solid Tumor
Intervention:
Drug: YL242
Drug: YL242
Pembrolizumab
Drug: YL242
5-FU
LV
Drug: YL242
Pembrolizumab
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: September 22, 2025
Target Sample Size: 424
Countries of Recruitment:
United States
Australia
China
Aust...